Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Lilly opens phase II trial of LY-3437943 in type 2 diabetes

June 14, 2021

Phase II proof-of-concept study of VX-864 in AATD meets primary endpoint

June 11, 2021

Yuhan Corp., Green Cross Corp. present new GLCT-1 inhibitors

June 11, 2021

First European CTA accepted for phase I/II study of INZ-701 in ABCC6 deficiency

June 10, 2021

Bayer patents prostaglandin E2 receptor EP3 subtype antagonists

June 10, 2021

Yuhan Corp. describes compositions including GDF15 variants

June 10, 2021

New GLP-1 receptor agonists identified at ILDONG Pharmaceutical

June 10, 2021

Yuhan Corp. and Green Cross Corp. present ceramide glucosyltransferase inhibitors

June 9, 2021

New mucolipin-1 activators identified at Libra Therapeutics

June 9, 2021

Bayer identifies new PTGER3 antagonists

June 7, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...